Lucas Moreno

Lucas Moreno is a paediatric oncologist dedicated to early phase clinical trials and neuroblastoma. He trained in La Fe (Valencia, Spain), started his career in the Royal Marsden Hospital (London, UK) under the mentorship of Andy Pearson.

From 2013 to 2019, he led the Clinical Trials Unit at Hospital Niño Jesus in Madrid, Spain and, from 2019, he leads the Division of Pediatric Hematology and Oncology at Vall d'Hebron University Hospital & Comprehensive Cancer Centre in Barcelona.

He is an active member of SIOPEN and Innovative Therapies for Children with Cancer (ITCC) consortia, and has led the international BEACON-Neuroblastoma randomised trial that recruited 225 patients with relapsed and refractory neuroblastoma and is currently working to set up its continuation, the BEACON2 trial.

His research interests are precision medicine and biomarkers, drug development and clinical trial methodology. He is member of the SIOPEN Executive Committee from 2017. He has been Vice-President (2020-2022) and President Elect (2023) and is from January 2024 on President of SIOPEN.